Related Experiment Video
Updated: Feb 22, 2026
08:25
An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation
Published on: April 27, 2021
2.7K
Midostaurin: a magic bullet that blocks mast cell expansion and activation
P Valent1, C Akin2, K Hartmann3
1Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria;; Division of Hematology & Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria;.
Summary
Midostaurin effectively treats advanced systemic mastocytosis (SM) by targeting KIT mutations, reducing neoplastic mast cells (MC), and improving survival. It also shows promise for indolent SM with severe symptoms.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Systemic mastocytosis (SM) presents with cosmetic issues, mediator symptoms, and organ damage due to mast cell (MC) infiltration.
- Neoplastic MC expansion in SM is driven by KIT mutations, primarily D816V, and activated via IgE-dependent pathways.
- Midostaurin (PKC412) inhibits KIT kinase activity, counteracting neoplastic MC growth and IgE-mediated mediator release.
Purpose of the Study:
- To evaluate the efficacy and safety of midostaurin in patients with advanced systemic mastocytosis.
- To assess midostaurin's impact on neoplastic mast cell burden, mediator symptoms, and patient survival.
- To explore potential applications of midostaurin in indolent SM and mast cell activation syndromes.
Main Methods:
- A multi-center phase II clinical trial was conducted.
- Patients with advanced systemic mastocytosis received midostaurin treatment.
- Outcomes measured included overall response rate, mast cell burden, survival, and symptom improvement.
Main Results:
- Midostaurin achieved a 60% overall response rate in advanced SM patients.
- The treatment led to a significant reduction in neoplastic mast cell burden across organs.
- Midostaurin improved overall survival, relapse-free survival, and quality of life compared to historical data.
Conclusions:
- Midostaurin is an effective treatment for advanced systemic mastocytosis, demonstrating significant clinical benefits.
- Midostaurin's ability to deplete and deactivate mast cells suggests potential utility in indolent SM and MC activation syndromes.
- Further studies are warranted to confirm midostaurin's value in these additional indications.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.0K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.0K
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
1.9K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.9K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
1.8K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.8K
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
1.1K
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
1.1K
01:19Antiasthma Drugs: Leukotriene Modifiers
2.0K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.0K
01:15Drugs that Stabilize Microtubules
2.8K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K